M&A Deal Summary

Ardian Acquires ESIM Chemicals

On June 22, 2015, private equity firm Ardian acquired chemicals company ESIM Chemicals from DPx Holdings BV

Acquisition Highlights
  • This is Ardian’s 8th transaction in the Chemicals sector.
  • This is Ardian’s 2nd transaction in Austria.
Investment Fate
  • ESIM Chemicals was sold to a consortium of financial buyers in 2018.

M&A Deal Summary

Date 2015-06-22
Target ESIM Chemicals
Sector Chemicals
Buyer(s) Ardian
Sellers(s) DPx Holdings BV
Deal Type Divestiture

Target

ESIM Chemicals

Linz, Austria
ESIM Chemicals is a global provider of high-quality agricultural and crop protection chemicals, intermediates and maleic anhydride tree chemicals, focusing on partnering with companies in the custom synthesis of their unique compounds and offer a portfolio of fine chemical products critical to multiple industries. The company has more than 75 years of experience in transforming innovative ideas into scalable supplies of advanced fine chemical products and intermediates using state of the art facilities. ESIM Chemicals was founded in 2015 and is based in Linz, Austria.

Search 214,503 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Ardian

Paris, France

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 1996
PE ASSETS 127.0B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

Ardian is a mega-sized diversified investment group focused on opportunities worldwide. Ardian invests across and manages funds focused on small and mid-sized buyouts, growth capital financings, mezzanine, infrastructure, real estate, and co-investment opportunities. Ardian's small-buyouts group targets controlling interests in French, German, and Italian businesses valued up to €100 million. It's mid-sized buyout group seeks businesses valued up €1.5 billion and does not have any geographic limitations. The Infrastructure team looks for European opportunities and can commit up to €1 billion per transaction. The Mezzanine group supports junior capital commitments of €5 to €80 million. In addition to direct investing, Ardian also manages various private equity fund-of-funds. Ardian was founded in 1996 and is based in Paris.


DEAL STATS #
Overall 241 of 464
Sector: Chemicals M&A 8 of 11
Type: Divestiture M&A Deals 15 of 34
Country: Austria M&A 2 of 4
Year: 2015 M&A 14 of 27
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-06-22 Biomnis SA

Lyon, France

Biomnis, formerly Laboratoire Marcel Mérieux, is a provider of pathological analysis in the fields of molecular diagnostics, tissue, fertility treatment and specialised biochemistry. It provides services on behalf of laboratories throughout France, operating two specialist sites in Paris and Lyon, with further sites in Paris, Lyon, Bordeaux, Dublin and Dubai. The group also owns a fully integrated logistics operation, TSE, handling five million samples per annum, collected daily throughout France.

Sell €220M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-06-24 Brico Privé

Montredon, France

Brico Privé is a provider of professional-quality products at affordable prices. Bricoprivé.com was founded in 2012 and is based in Montredon, France.

Buy -

Seller(S) 1

SELLER

DPx Holdings BV

Framingham, Massachusetts, United States

Category Company
Founded 2014
Sector Life Science
Employees8,000
DESCRIPTION

DPx Holdings BV is a provider of development and manufacturing services, pharmaceutical products and technologies and select chemical products for other industries. DPx Holdings was founded in 2014 and is based in Framingham, Massachusetts.


DEAL STATS #
Overall 1 of 1
Sector: Chemicals M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: Austria M&A 1 of 1
Year: 2015 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-08-27 Gallus Biopharmaceuticals

St. Louis, Montana, United States

Gallus BioPharmaceuticals is a contract manufacturing company offering exceptional contract services to its clients. Gallus’ world-class facility in St. Louis is distinguished by nearly three decades of biologics development and over a decade of commercial cGMP manufacturing, including the ongoing manufacture of Remicade® and Stelara® for Janssen Pharmaceuticals.

Buy -